Sensei Biotherapeutics (NASDAQ:FTH) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Sensei Biotherapeutics (NASDAQ:FTH) posted its quarterly earnings results on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.13), Zacks reports.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock traded up $0.75 during midday trading on Tuesday, hitting $19.98. The company’s stock had a trading volume of 30,330 shares, compared to its average volume of 251,708. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14. The business’s 50-day simple moving average is $28.55. The firm has a market capitalization of $516.28 million, a P/E ratio of -0.14 and a beta of -0.14.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Oppenheimer assumed coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, William Blair initiated coverage on Sensei Biotherapeutics in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.